Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
ALCOBRA LTD. (ARCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/04/2020 |
GN
| Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate |
| 08/11/2020 |
GN
| Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study |
| 08/10/2020 |
GN
| Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update |
| 08/06/2020 |
GN
| Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer |
| 07/31/2020 |
GN
| Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares |
| 07/28/2020 |
GN
| Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock |
| 07/21/2020 |
GN
| Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19 |
| 07/01/2020 |
GN
| Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board |
| 06/05/2020 |
GN
| Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency |
| 05/21/2020 |
GN
| Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics |
| 05/08/2020 |
GN
| Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19) |
| 05/04/2020 |
GN
| Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020 |
| 04/16/2020 |
GN
| Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock |
| 04/15/2020 |
GN
| Arcturus Therapeutics Announces Proposed Public Offering of Common Stock |
| 04/13/2020 |
GN
| Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency |
| 04/09/2020 |
GN
| Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine |
| 03/27/2020 |
GN
| Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System |
| 03/04/2020 |
GN
| Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™ |
| 02/19/2020 |
GN
| Arcturus Therapeutics to Present at Two Investor Conferences in March |
| 01/08/2020 |
GN
| Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer |
| 11/04/2019 |
GN
| Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th |
| 10/02/2019 |
GN
| Arcturus Therapeutics to Present at Three Upcoming Investor Conferences |
| 09/23/2019 |
GN
| Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors |
| 08/26/2019 |
GN
| Arcturus Therapeutics To Present at Two Investor Conferences in September |
| 08/07/2019 |
GN
| Arcturus to Report Corporate Overview and Financial Results on August 15 |
| 07/15/2019 |
GN
| Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D. |
| 06/27/2019 |
GN
| Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency |
| 06/19/2019 |
GN
| Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases |
| 05/20/2019 |
GN
| Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics |
| 11/16/2017 |
GN
| Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market |
| 11/02/2017 |
GN
| Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7 |
| 09/27/2017 |
GN
| Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge |
| 08/11/2017 |
GN
| Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update |
| 06/23/2017 |
GN
| Alcobra Updates on its Review of Strategic Alternatives |
|
|
|